https://wiki.tiffa.net/w/index.php?action=history&feed=atom&title=Translations%3ADiscovery_and_development_of_angiotensin_receptor_blockers%2F25%2FenTranslations:Discovery and development of angiotensin receptor blockers/25/en - Revision history2026-07-13T11:38:12ZRevision history for this page on the wikiMediaWiki 1.43.0https://wiki.tiffa.net/w/index.php?title=Translations:Discovery_and_development_of_angiotensin_receptor_blockers/25/en&diff=131482&oldid=prevFuzzyBot: Importing a new version from external source2024-03-28T01:25:31Z<p>Importing a new version from external source</p>
<p><b>New page</b></p><div>Replacing the 2-carboxy-benzamido-group with a 2-carboxy-[[phenyl]]-group created the [[lipophilic]] [[biphenyl]]-containing EXP-7711, which exhibited good oral activity but slightly less affinity for the AT<sub>1</sub> receptor. <br /><br />
<br />
Then the [[chemical polarity|polar]] carboxyl group was replaced with a more lipophilic [[tetrazole]] group in order to increase oral bioavailability and duration of action further and the compound thus formed was named [[losartan]]. This development took place in 1986 and losartan became the first successful [[angiotensin II receptor antagonist|Ang II antagonist]] drug, approved as such in the United States in 1995 and was marketed by [[Merck & Co.|Merck]].</div>FuzzyBot